Follow
Daniel SW Tan
Title
Cited by
Cited by
Year
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
New England Journal of Medicine 370 (13), 1189-1197, 2014
18132014
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
11772017
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, ...
Nature 557 (7706), 575-579, 2018
10362018
Isolation and retrieval of circulating tumor cells using centrifugal forces
HW Hou, ME Warkiani, BL Khoo, ZR Li, RA Soo, DSW Tan, WT Lim, J Han, ...
Scientific reports 3 (1), 1259, 2013
8542013
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ...
New England Journal of Medicine 383 (10), 944-957, 2020
6562020
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ...
Nature medicine 18 (4), 521-528, 2012
6562012
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
6282020
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ...
Journal of thoracic oncology 13 (9), 1248-1268, 2018
6112018
Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells
ME Warkiani, G Guan, KB Luan, WC Lee, AAS Bhagat, PK Chaudhuri, ...
Lab on a Chip 14 (1), 128-137, 2014
6082014
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
5682020
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
The lancet oncology 17 (4), 452-463, 2016
4992016
Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency
Y Simoni, M Fehlings, HN KlÝverpris, N McGovern, SL Koo, CY Loh, ...
Immunity 46 (1), 148-161, 2017
4332017
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
3932020
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
A Drilon, ZI Hu, GGY Lai, DSW Tan
Nature reviews Clinical oncology 15 (3), 151-167, 2018
3362018
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ...
Journal of Thoracic Oncology 16 (10), 1647-1662, 2021
3162021
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ...
Annals of Oncology 31 (10), 1320-1335, 2020
3012020
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ...
The lancet oncology 22 (7), 959-969, 2021
2922021
Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor†…
YL Wu, L Zhang, DW Kim, X Liu, DH Lee, JCH Yang, MJ Ahn, ...
Journal of Clinical Oncology 36 (31), 3101-+, 2018
2772018
Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
AC Tan, DSW Tan
Journal of Clinical Oncology 40 (6), 611-625, 2022
2662022
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS†…
YL Wu, D Planchard, S Lu, H Sun, N Yamamoto, DW Kim, DSW Tan, ...
Annals of Oncology 30 (2), 171-210, 2019
2602019
The system can't perform the operation now. Try again later.
Articles 1–20